Symptoms and General Pathology

All Conditions

Neoplasms

Gland and Hormone Related Diseases

Diseases and Abnormalities at or Before Birth

Digestive System Diseases

Rare Diseases

Syndrome

Endocrine Gland Neoplasms

Multiple Endocrine Neoplasia

Gastrinoma

Zollinger-Ellison Syndrome

Endocrine System Diseases

Neoplasms, Multiple Primary

Neoplastic Syndromes, Hereditary

Genetic Diseases, Inborn

Paraneoplastic Syndromes

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Ulcer

Peptic Ulcer

Duodenal Diseases

Intestinal Diseases

Stomach Diseases

Carcinoma

Carcinoma, Islet Cell

Adenocarcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Pancreatic Neoplasms

Pancreatic Diseases

Pancreatic Cancer

Gastrointestinal Agents

All Drugs and Chemicals

Lansoprazole

Dexlansoprazole

Antacids

Anti-Ulcer Agents

Proton Pump Inhibitors

Enzyme Inhibitors

This is an open label, non-randomized, uncontrolled, single group study designed to treat patients with Zollinger-Ellison Syndrome and other hypersecretory conditions by controlling gastric acid production; to heal and prevent relapses of peptic ulcers and symptoms; to monitor the safety and efficacy of this treatment.

Lansoprazole 30mg capsules. dose is individualized to each subject based on gastric acid production. The range is 30 mg to 450 mg daily.

Lansoprazole (Prevacid)

C. Mel Wilcox, M.D.

The purpose of this study is to study the safety and efficacy of high dose Prevacid in the long-term treatment of patients who secrete abnormally large amounts of gastric acid.

The aim of this protocol is to study the medical management of acid hypersecretory states including Zollinger-Ellison using Prevacid. The immediate objective is to heal peptic ulcers and eliminate symptoms and in the long term to prevent relapse of symptoms, lesions and complications. Other objectives include observation of the efficacy in controlling gastric acid production and of the safety of high dose, long-term use of Prevacid.

Treatment of Zollinger-Ellison Syndrome With Prevacid

Long-Term Study of the Efficacy and Safety of Lansoprazole in the Treatment of Zollinger-Ellison and Other Acid Hypersecretors

number of participants with control of gastric acid production

The median survival from the time of diagnosis

Takeda Pharmaceuticals North America, Inc.

Charles Mel Wilcox, MD

Prinicle Investigator

Single Group

Age, Categorical

Age Continuous

Sex: Female, Male

United States

Region of Enrollment

Dr. C. Mel Wilcox

Long-term Medical(Non-surgical)Control of Gastric Acid Production Assessed From Time of Study Enrollment, up to 240 Months Post Enrollment.

The Median Survival From the Time of Diagnosis.

Overall Study

Spots Global Cancer Trial Database for lansoprazole (prevacid)